Raynauds Disease - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Raynauds Disease - Pipeline Review, H1 2016', provides an overview of the Raynauds Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Raynauds Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Raynauds Disease - The report reviews pipeline therapeutics for Raynauds Disease by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Raynauds Disease therapeutics and enlists all their major and minor projects - The report assesses Raynauds Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Raynauds Disease Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Raynauds Disease - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Raynauds Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Raynauds Disease Overview 6 Therapeutics Development 7 Pipeline Products for Raynauds Disease - Overview 7 Raynauds Disease - Therapeutics under Development by Companies 8 Raynauds Disease - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Raynauds Disease - Products under Development by Companies 12 Raynauds Disease - Companies Involved in Therapeutics Development 13 Allergan Plc 13 Apricus Biosciences, Inc. 14 Bayer AG 15 Covis Pharmaceuticals, Inc. 16 Human Stem Cells Institute 17 Raynauds Disease - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 acetylcysteine - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 alprostadil - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 ELS-140 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Neovasculgen - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 nitroglycerin - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 onabotulinumtoxin A - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 riociguat - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Raynauds Disease - Recent Pipeline Updates 40 Raynauds Disease - Dormant Projects 54 Raynauds Disease - Discontinued Products 55 Raynauds Disease - Product Development Milestones 56 Featured News & Press Releases 56 Mar 08, 2016: Apricus Biosciences to Present at the 28th Annual ROTH Conference 56 Feb 02, 2016: Apricus Biosciences to Present at the 18th Annual BIO CEO & Investor Conference, Provide Update on Vitaros 56 Aug 05, 2015: Apricus Biosciences to Provide Update On The European Launch of Vitaros at the Canaccord Genuity 35th Annual Growth Conference 56 Apr 28, 2015: Apricus Biosciences to Present at Two Investor Conferences in May 56 Jan 27, 2015: Apricus Biosciences Announces Issuance of U.S. Patent for RayVa 57 Dec 04, 2014: Apricus Biosciences Announces First Patient Enrolled In Phase 2a Clinical Trial For RayVa In Patients With Raynaud's Phenomenon 57 Oct 13, 2014: Apricus Biosciences Announces Notice of Allowance of U.S. Patent Application for RayVa 58 Oct 01, 2014: Apricus Biosciences to Present at the 13th Annual BIO Investor Forum 59 May 12, 2014: Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa for Secondary Raynaud's Phenomenon 59 Dec 13, 2012: MediQuest Therapeutics To Conduct Meetings At J.P. Morgan Conference Regarding Phase III Topical Formulation Vascana 59 Appendix 61 Methodology 61 Coverage 61 Secondary Research 61 Primary Research 61 Expert Panel Validation 61 Contact Us 61 Disclaimer 62
List of Tables
Number of Products under Development for Raynauds Disease, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Raynauds Disease - Pipeline by Allergan Plc, H1 2016 13 Raynauds Disease - Pipeline by Apricus Biosciences, Inc., H1 2016 14 Raynauds Disease - Pipeline by Bayer AG, H1 2016 15 Raynauds Disease - Pipeline by Covis Pharmaceuticals, Inc., H1 2016 16 Raynauds Disease - Pipeline by Human Stem Cells Institute, H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Raynauds Disease Therapeutics - Recent Pipeline Updates, H1 2016 40 Raynauds Disease - Dormant Projects, H1 2016 54 Raynauds Disease - Discontinued Products, H1 2016 55
List of Figures
Number of Products under Development for Raynauds Disease, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Targets, H1 2016 19 Number of Products by Stage and Targets, H1 2016 19 Number of Products by Mechanism of Actions, H1 2016 21 Number of Products by Stage and Mechanism of Actions, H1 2016 21 Number of Products by Routes of Administration, H1 2016 23 Number of Products by Stage and Routes of Administration, H1 2016 23 Number of Products by Molecule Types, H1 2016 25 Number of Products by Stage and Molecule Types, H1 2016 25
Global heat transfer fluids market size is likely to be valued at USD 3.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing demand for for heat recovery management in industries such as metal processing, pharmaceuticaRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.